Amneal Pharmaceuticals Inc
General ticker "AMRX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $2.5B
Amneal Pharmaceuticals Inc follows the US Stock Market performance with the rate: 65.5%.
Estimated limits based on current volatility of 1.7%: low 7.57$, high 7.83$
Factors to consider:
- Current price 10.8% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.83$, 7.03$]
- 2024-12-30 to 2025-12-30 estimated range: [4.81$, 8.26$]
Financial Metrics affecting the AMRX estimates:
- Negative: negative Net income
- Positive: 0.10 < Non-GAAP EPS, $ of 0.64
- Positive: Operating cash flow per share per price, % of 39.97 > 12.76
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
- Positive: 1.03 < Operating profit margin, % of 8.54
- Negative: Industry operating profit margin (median), % of -70.04 <= 2.14
Short-term AMRX quotes
Long-term AMRX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $2,068.47MM | $1,945.60MM | $2,393.61MM |
| Operating Expenses | $1,915.75MM | $2,040.53MM | $2,189.23MM |
| Operating Income | $152.72MM | $-94.93MM | $204.37MM |
| Non-Operating Income | $-121.35MM | $-153.20MM | $-244.64MM |
| Interest Expense | $136.32MM | $158.38MM | $210.63MM |
| R&D Expense | $209.56MM | $200.05MM | $167.78MM |
| Income(Loss) | $31.37MM | $-248.13MM | $-40.27MM |
| Taxes | $11.20MM | $6.66MM | $8.45MM |
| Profit(Loss) | $20.17MM | $-254.79MM | $-48.72MM |
| Stockholders Equity | $366.97MM | $183.98MM | $19.78MM |
| Inventory | $489.39MM | $530.74MM | $581.38MM |
| Assets | $3,939.66MM | $3,799.34MM | $3,472.57MM |
| Operating Cash Flow | $241.82MM | $65.10MM | $345.58MM |
| Capital expenditure | $52.64MM | $90.59MM | $69.19MM |
| Investing Cash Flow | $-194.18MM | $-174.31MM | $-69.19MM |
| Financing Cash Flow | $-138.12MM | $-106.62MM | $-212.57MM |
| Earnings Per Share* | $0.14 | $-1.69 | $-0.48 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.